Can AcroCyte turn a $4.3m ARPA-H award into a scalable bioartificial kidney platform?
AcroCyte’s $4.3m ARPA-H-backed RACE project targets scalable autologous kidney organoids, but manufacturing and animal data remain the key tests.
Pharma & Biotech
Medical Devices & Diagnostics
HistoSonics just cleared a major Asia hurdle. Could histotripsy move beyond liver tumors next?
HistoSonics cleared Taiwan, but the bigger test is whether histotripsy can scale from liver tumors into broader oncology use.